UAE HIV Therapeutics Market Analysis Report [2022-30] I Insights10

UAE HIV Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the UAE HIV therapeutics market will reach a value of $92.01 Mn from $68.8 Mn in 2022, growing at a CAGR of 3.7% during 2022-2030. The market is primarily dominated by local players such as Julphar, Neopharma, and Emirates Pharmaceutical Industries. The market for HIV/AIDS treatment in the UAE is primarily driven by government funding and initiatives, although private sector investment is also playing a role in the development of new treatments and diagnostic tools. The HIV therapeutics market in UAE is segmented by type, product, geography, end user, and distribution channel.

ID: IN10AEPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: UAE AUTHOR: Dr. Vishwa Modhia

Buy Now

UAE HIV Therapeutics Market Analysis Summary

By 2030, it is anticipated that the UAE HIV therapeutics market will reach a value of $92.01 Mn from $68.8 Mn in 2022, growing at a CAGR of 3.7% during 2022-2030.

By 2021, the adult HIV/AIDS prevalence rate in the UAE is projected to be 0.3%. The UAE is ranked 86th in terms of other nations in terms of HIV prevalence. In 2019, the UAE government’s healthcare expenditures accounted for 4.3% of its GDP. The exponential rise in medical costs and the growing demand for better healthcare in the UAE have given public-private partnerships a lot of encouragement. The government is working with international organizations such as the World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) to combat the disease in the UAE.

uae HIV therapeutics market analysis

Market Dynamics

Market Growth Drivers Analysis

HIV infection is becoming more common in the UAE. The Middle East is one of the top two regions in the world where the HIV epidemic is spreading the fastest. The majority of HIV cases were discovered in Dubai and Sharjah, which is indicative of the two emirates' larger populations and perhaps higher levels of risky behaviors given that both cities may be more exposed to high-risk HIV-related phenomena.

Market Restraints

Among university students in the UAE, misconceptions about the methods of transmission persist and differ based on factors such as gender, nationality, marital status, and level of study. HIV/Aids are linked to taboos and the notion that HIV can only be transmitted through illicit sexual interactions, which furthers the stigmatization of those who have the illness.

Competitive Landscape

Key Players

Julphar (ARE)
Neopharma (ARE)
Emirates Pharmaceutical Industries (ARE)
Abu Dhabi National Pharmaceuticals (ARE)
Gilead Sciences (ARE)
Pfizer
Bristol-Myers Squibb
GlaxoSmithKline

Healthcare Policies

The primary body in charge of regulating all aspects of the pharmaceutical industry in the UAE is the Ministry of Health (MOH). In addition to managing the healthcare industry in the Northern Emirates, the Ministry of Health develops the UAE's national medical and healthcare policy.

Reimbursement Scenarios

An obligatory health insurance model provides funding for the country's healthcare system. Employers or sponsors, the government (which finances a single-payer health insurance program for residents), and people who pay for their own expenses out of pocket and insurance premiums are the main funding sources in Abu Dhabi. Patients who are insured by the government are treated by private healthcare providers, who are reimbursed by the UAE government. Since 2016, uninsured expats and UAE nationals have been legally allowed to receive free HIV treatment. However, in practice, this provision only applies to citizens because of the deportation laws.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.